List of works by Martin R Gaudinski

A proof of concept for structure-based vaccine design targeting RSV in humans

scientific article published on 01 August 2019

Atopic Dermatitis and Allergic Urticaria: Cutaneous Manifestations of Immunodeficiency

scientific article published on 28 October 2016

Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality

scientific article published on 01 June 2020

Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant

scientific article published on 17 July 2008

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

scientific article published on 28 July 2020

Feridex preloading permits tracking of CNS-resident macrophages after transient middle cerebral artery occlusion

scientific article published on 06 May 2009

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

scientific article published on 17 March 2022

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

scientific article published on 28 August 2019

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

scientific article published on 24 January 2018

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

scientific article published on 4 December 2017

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

article by Martin R Gaudinski et al published 2 March 2019 in The Lancet

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

scientific article